Cargando…

Bleomycin Concentration in Patients’ Plasma and Tumors after Electrochemotherapy. A Study from InspECT Group

The plasma concentration profile of bleomycin in the distribution phase of patients younger than 65 years is needed to determine the suitable time interval for efficient application of electric pulses during electrochemotherapy. Additionally, bleomycin concentrations in the treated tumors for effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Groselj, Ales, Bosnjak, Masa, Krzan, Mojca, Kosjek, Tina, Bottyán, Kriszta, Plesnik, Helena, Jamsek, Crt, Cemazar, Maja, Kis, Erika, Sersa, Gregor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469090/
https://www.ncbi.nlm.nih.gov/pubmed/34575400
http://dx.doi.org/10.3390/pharmaceutics13091324
_version_ 1784573841224237056
author Groselj, Ales
Bosnjak, Masa
Krzan, Mojca
Kosjek, Tina
Bottyán, Kriszta
Plesnik, Helena
Jamsek, Crt
Cemazar, Maja
Kis, Erika
Sersa, Gregor
author_facet Groselj, Ales
Bosnjak, Masa
Krzan, Mojca
Kosjek, Tina
Bottyán, Kriszta
Plesnik, Helena
Jamsek, Crt
Cemazar, Maja
Kis, Erika
Sersa, Gregor
author_sort Groselj, Ales
collection PubMed
description The plasma concentration profile of bleomycin in the distribution phase of patients younger than 65 years is needed to determine the suitable time interval for efficient application of electric pulses during electrochemotherapy. Additionally, bleomycin concentrations in the treated tumors for effective tumor response are not known. In this study, the pharmacokinetic profile of bleomycin in the distribution phase in 12 patients younger than 65 years was determined. In 17 patients, the intratumoral bleomycin concentration was determined before the application of electric pulses. In younger patients, the pharmacokinetics of intravenously injected bleomycin demonstrated a faster plasma clearance rate than that in patients older than 65 years. This outcome might indicate that the lowering of the standard bleomycin dose of 15,000 IU/m(2) with intravenous bleomycin injection for electrochemotherapy is not recommended in younger patients. Based on the plasma concentration data gathered, a time interval for electrochemotherapy of 5–15 min after bleomycin injection was determined. The median bleomycin concentration in tumors 8 min after bleomycin injection, at the time of electroporation, was 170 ng/g. Based on collected data, the reduction of the bleomycin dose is not recommended in younger patients; however, a shortened time interval for application of electric pulses in electrochemotherapy to 5–15 min after intravenous bleomycin injection should be considered.
format Online
Article
Text
id pubmed-8469090
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84690902021-09-27 Bleomycin Concentration in Patients’ Plasma and Tumors after Electrochemotherapy. A Study from InspECT Group Groselj, Ales Bosnjak, Masa Krzan, Mojca Kosjek, Tina Bottyán, Kriszta Plesnik, Helena Jamsek, Crt Cemazar, Maja Kis, Erika Sersa, Gregor Pharmaceutics Article The plasma concentration profile of bleomycin in the distribution phase of patients younger than 65 years is needed to determine the suitable time interval for efficient application of electric pulses during electrochemotherapy. Additionally, bleomycin concentrations in the treated tumors for effective tumor response are not known. In this study, the pharmacokinetic profile of bleomycin in the distribution phase in 12 patients younger than 65 years was determined. In 17 patients, the intratumoral bleomycin concentration was determined before the application of electric pulses. In younger patients, the pharmacokinetics of intravenously injected bleomycin demonstrated a faster plasma clearance rate than that in patients older than 65 years. This outcome might indicate that the lowering of the standard bleomycin dose of 15,000 IU/m(2) with intravenous bleomycin injection for electrochemotherapy is not recommended in younger patients. Based on the plasma concentration data gathered, a time interval for electrochemotherapy of 5–15 min after bleomycin injection was determined. The median bleomycin concentration in tumors 8 min after bleomycin injection, at the time of electroporation, was 170 ng/g. Based on collected data, the reduction of the bleomycin dose is not recommended in younger patients; however, a shortened time interval for application of electric pulses in electrochemotherapy to 5–15 min after intravenous bleomycin injection should be considered. MDPI 2021-08-24 /pmc/articles/PMC8469090/ /pubmed/34575400 http://dx.doi.org/10.3390/pharmaceutics13091324 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Groselj, Ales
Bosnjak, Masa
Krzan, Mojca
Kosjek, Tina
Bottyán, Kriszta
Plesnik, Helena
Jamsek, Crt
Cemazar, Maja
Kis, Erika
Sersa, Gregor
Bleomycin Concentration in Patients’ Plasma and Tumors after Electrochemotherapy. A Study from InspECT Group
title Bleomycin Concentration in Patients’ Plasma and Tumors after Electrochemotherapy. A Study from InspECT Group
title_full Bleomycin Concentration in Patients’ Plasma and Tumors after Electrochemotherapy. A Study from InspECT Group
title_fullStr Bleomycin Concentration in Patients’ Plasma and Tumors after Electrochemotherapy. A Study from InspECT Group
title_full_unstemmed Bleomycin Concentration in Patients’ Plasma and Tumors after Electrochemotherapy. A Study from InspECT Group
title_short Bleomycin Concentration in Patients’ Plasma and Tumors after Electrochemotherapy. A Study from InspECT Group
title_sort bleomycin concentration in patients’ plasma and tumors after electrochemotherapy. a study from inspect group
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469090/
https://www.ncbi.nlm.nih.gov/pubmed/34575400
http://dx.doi.org/10.3390/pharmaceutics13091324
work_keys_str_mv AT groseljales bleomycinconcentrationinpatientsplasmaandtumorsafterelectrochemotherapyastudyfrominspectgroup
AT bosnjakmasa bleomycinconcentrationinpatientsplasmaandtumorsafterelectrochemotherapyastudyfrominspectgroup
AT krzanmojca bleomycinconcentrationinpatientsplasmaandtumorsafterelectrochemotherapyastudyfrominspectgroup
AT kosjektina bleomycinconcentrationinpatientsplasmaandtumorsafterelectrochemotherapyastudyfrominspectgroup
AT bottyankriszta bleomycinconcentrationinpatientsplasmaandtumorsafterelectrochemotherapyastudyfrominspectgroup
AT plesnikhelena bleomycinconcentrationinpatientsplasmaandtumorsafterelectrochemotherapyastudyfrominspectgroup
AT jamsekcrt bleomycinconcentrationinpatientsplasmaandtumorsafterelectrochemotherapyastudyfrominspectgroup
AT cemazarmaja bleomycinconcentrationinpatientsplasmaandtumorsafterelectrochemotherapyastudyfrominspectgroup
AT kiserika bleomycinconcentrationinpatientsplasmaandtumorsafterelectrochemotherapyastudyfrominspectgroup
AT sersagregor bleomycinconcentrationinpatientsplasmaandtumorsafterelectrochemotherapyastudyfrominspectgroup